Ciamexon in the low dose streptozotocin induced diabetes of mice
- PMID: 3325216
Ciamexon in the low dose streptozotocin induced diabetes of mice
Abstract
This article is concerned with suppression of the development of diabetes experimentally induced by multiple injections of subdiabetogenic doses of streptozotocin (4 x 45 mg/kg/d) in mice (CD 1 and C57B16). Streptozotocin injections were followed by hyperglycemia and mononuclear cell infiltration of islets (insulitis). Ciamexon is a new immuno-modulating agent with promising effects in experimental models of autoimmune diseases and practically no toxic side effects. When Ciamexon was given before streptozotocin treatment blood glucose levels in the parenteral glucose tolerance test were suppressed in a dose dependent way. 60 days after streptozotocin application the percentage of islets showing insulitis or even necrosis was reduced in the Ciamexon treated group compared to the streptozotocin only group. In contrast, Cyclosporin A had a detrimental effect on diabetes in this model although blood levels were proved to be in the therapeutic range. From these results we conclude that Ciamexon should be tested for its effect in human type I diabetes.
Similar articles
-
Different effect of two immunomodulating agents cyclosporin A and ciamexon on the insulin metabolism of cultured mouse islets.Diabetes Res. 1987 Mar;4(3):121-3. Diabetes Res. 1987. PMID: 3038453
-
Effects of cyclosporin on autoimmune diabetes induced in mice by streptozotocin: beta cell-toxicity and rebound of insulitis after cessation of treatment.Diabete Metab. 1988 Jul-Aug;14(4):455-62. Diabete Metab. 1988. PMID: 3066654
-
The radical scavenger edaravone counteracts diabetes in multiple low-dose streptozotocin-treated mice.Eur J Pharmacol. 2008 Mar 31;583(1):164-9. doi: 10.1016/j.ejphar.2008.01.033. Epub 2008 Feb 5. Eur J Pharmacol. 2008. PMID: 18291360
-
Cyclosporin A improves the glucose tolerance of young diabetics.Nutr Rev. 1989 Apr;47(4):123-4. doi: 10.1111/j.1753-4887.1989.tb02813.x. Nutr Rev. 1989. PMID: 2660021 Review. No abstract available.
-
Biological response modifiers and differentiation inducers. Current status in cancer research.Drugs. 1983 Sep;26(3):185-90. doi: 10.2165/00003495-198326030-00001. Drugs. 1983. PMID: 6352236 Review. No abstract available.
Cited by
-
Essential fatty acid deficiency prevents multiple low-dose streptozotocin-induced diabetes in naive and cyclosporin-treated low-responder murine strains.Acta Diabetol. 1995 Jun;32(2):125-30. doi: 10.1007/BF00569571. Acta Diabetol. 1995. PMID: 7579534
-
Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.Drugs. 1993 Jun;45(6):953-1040. doi: 10.2165/00003495-199345060-00007. Drugs. 1993. PMID: 7691501 Review.
-
Essential fatty acid deficiency prevents multiple low-dose streptozotocin-induced diabetes in CD-1 mice.Proc Natl Acad Sci U S A. 1988 Aug;85(16):6137-41. doi: 10.1073/pnas.85.16.6137. Proc Natl Acad Sci U S A. 1988. PMID: 3045812 Free PMC article.
-
The anti-diabetogenic effect of essential fatty acid deficiency in multiple low-dose streptozotocin-treated mice persists if essential fatty acid repletion occurs outside of a brief window of susceptibility.Diabetologia. 1991 Oct;34(10):709-14. doi: 10.1007/BF00401515. Diabetologia. 1991. PMID: 1835705
-
Insulin-like growth factor-1 stimulates regulatory T cells and suppresses autoimmune disease.EMBO Mol Med. 2014 Nov;6(11):1423-35. doi: 10.15252/emmm.201303376. EMBO Mol Med. 2014. PMID: 25339185 Free PMC article.